Skip to main content
Erschienen in: Investigational New Drugs 3/2013

01.06.2013 | PRECLINICAL STUDIES

Dual modulation of JNK and Akt signaling pathways by chaetoglobosin K in human lung carcinoma and ras-transformed epithelial cells

verfasst von: Amna Ali, Tatyana S. Sidorova, Diane F. Matesic

Erschienen in: Investigational New Drugs | Ausgabe 3/2013

Einloggen, um Zugang zu erhalten

Summary

Chaetoglobosin K (ChK) is a natural product that inhibits anchorage-dependent and anchorage-independent growth of ras-transformed cells, prevents tumor-promoter disruption of cell-cell communication, and reduces Akt activation in tumorigenic cells. This study demonstrates how ChK modulates the JNK pathway in ras-transformed and human lung carcinoma cells and investigates regulatory mechanisms controlling ChK’s effect on the Akt and JNK signaling pathways. Human lung carcinoma and ras-transformed epithelial cell lines treated with ChK or vehicle for varying times were assayed for cell growth or extracted for total proteins for western blot analysis using phosphorylation site-specific antibodies to monitor changes in activation of JNK, Akt, and other signaling enzymes. Results show that ChK inhibited both Akt and JNK phosphorylation at key activation sites in ras-transformed cells as well as human lung carcinoma cells. Downstream effectors of both kinases were accordingly affected. Direct upstream kinases of JNK were not affected by ChK. Wortmannin and LY294002, two PI3 kinase inhibitors, inhibited Akt but not JNK phosphorylation in ras-transformed cells. This report establishes the dual inhibitory effect of ChK on both the Akt and JNK signaling pathways in ras-transformed epithelial and human carcinoma cells. The unique effect of ChK on these two key pathways involved in carcinogenesis earmarks ChK for further studies to determine its molecular target(s) and in vivo anti-tumor potential.
Literatur
1.
Zurück zum Zitat Schechter AL, Stern DF, Vaidyanathan L, Decker SJ, Drebin JA, Greene MI et al (1984) The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen. Nature 312:513–516PubMedCrossRef Schechter AL, Stern DF, Vaidyanathan L, Decker SJ, Drebin JA, Greene MI et al (1984) The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen. Nature 312:513–516PubMedCrossRef
2.
Zurück zum Zitat Jou YS, Layhe B, Matesic DF, Chang CC, de Feijter AW, Lockwood L et al (1995) Inhibition of gap junctional intercellular communication and malignant transformation of rat liver epithelial cells by neu oncogene. Carcinogenesis 16:311–317PubMedCrossRef Jou YS, Layhe B, Matesic DF, Chang CC, de Feijter AW, Lockwood L et al (1995) Inhibition of gap junctional intercellular communication and malignant transformation of rat liver epithelial cells by neu oncogene. Carcinogenesis 16:311–317PubMedCrossRef
3.
Zurück zum Zitat Adjei AA (2001) Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer Inst 93:1062–1074PubMedCrossRef Adjei AA (2001) Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer Inst 93:1062–1074PubMedCrossRef
4.
Zurück zum Zitat Jain M, Arvanitis C, Chu K, Dewey W, Leonhardt E, Trinh M et al (2002) Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science 297:102–104PubMedCrossRef Jain M, Arvanitis C, Chu K, Dewey W, Leonhardt E, Trinh M et al (2002) Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science 297:102–104PubMedCrossRef
5.
Zurück zum Zitat Druker BJ (2002) STI571 (Gleevec™) as a paradigm for cancer therapy. Trends Mol Med 8:S14–S18PubMedCrossRef Druker BJ (2002) STI571 (Gleevec™) as a paradigm for cancer therapy. Trends Mol Med 8:S14–S18PubMedCrossRef
6.
Zurück zum Zitat Bezjak A, Tu D, Seymour L, Clark G, Trajkovic A, Zukin M et al (2006) Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 24:3831–3837PubMedCrossRef Bezjak A, Tu D, Seymour L, Clark G, Trajkovic A, Zukin M et al (2006) Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 24:3831–3837PubMedCrossRef
7.
Zurück zum Zitat Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY et al (2003) Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 21:2237–2246PubMedCrossRef Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY et al (2003) Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 21:2237–2246PubMedCrossRef
8.
Zurück zum Zitat Kris MG, Natale RB, Herbst RS, Lynch TJ Jr, Prager D, Belani CP et al (2003) Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290:2149–2158PubMedCrossRef Kris MG, Natale RB, Herbst RS, Lynch TJ Jr, Prager D, Belani CP et al (2003) Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290:2149–2158PubMedCrossRef
9.
Zurück zum Zitat Ross JS, Schenkein DP, Pietrusko R, Rolfe M, Linette GP, Stec J et al (2004) Targeted therapies for cancer 2004. Am J Clin Pathol 122:598–609PubMedCrossRef Ross JS, Schenkein DP, Pietrusko R, Rolfe M, Linette GP, Stec J et al (2004) Targeted therapies for cancer 2004. Am J Clin Pathol 122:598–609PubMedCrossRef
10.
Zurück zum Zitat Xiong HQ (2004) Molecular targeting therapy for pancreatic cancer. Cancer Chemother Pharmacol 54:S69–S77PubMed Xiong HQ (2004) Molecular targeting therapy for pancreatic cancer. Cancer Chemother Pharmacol 54:S69–S77PubMed
11.
Zurück zum Zitat Karapetis CS, Khambata-Ford S, Jonker DJ, O’Callaghan CJ, Tu D, Tebbutt NC et al (2008) K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359:1757–1765PubMedCrossRef Karapetis CS, Khambata-Ford S, Jonker DJ, O’Callaghan CJ, Tu D, Tebbutt NC et al (2008) K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359:1757–1765PubMedCrossRef
12.
13.
Zurück zum Zitat Rodriguez-Viciana P, Warne PH, Khwaja A, Marte BM, Pappin D, Das P et al (1997) Role of phosphoinositide 3-OH kinase in cell transformation and control of the actin cytoskeleton by Ras. Cell 89:457–467PubMedCrossRef Rodriguez-Viciana P, Warne PH, Khwaja A, Marte BM, Pappin D, Das P et al (1997) Role of phosphoinositide 3-OH kinase in cell transformation and control of the actin cytoskeleton by Ras. Cell 89:457–467PubMedCrossRef
15.
Zurück zum Zitat Vivanco I, Sawyers CI (2002) The phosphatidylinositol 3-kinase-Akt pathway in human cancer. Nat Rev Cancer 2:489–501PubMedCrossRef Vivanco I, Sawyers CI (2002) The phosphatidylinositol 3-kinase-Akt pathway in human cancer. Nat Rev Cancer 2:489–501PubMedCrossRef
16.
Zurück zum Zitat Stokoe D, Stephens LR, Copeland T, Gaffney PRJ, Reese CB, Painter GF et al (1997) Dual role of the phosphatidylinositol-3,4,5-trisphosphate in the activation of protein kinase B. Science 277:567–570PubMedCrossRef Stokoe D, Stephens LR, Copeland T, Gaffney PRJ, Reese CB, Painter GF et al (1997) Dual role of the phosphatidylinositol-3,4,5-trisphosphate in the activation of protein kinase B. Science 277:567–570PubMedCrossRef
17.
Zurück zum Zitat Yang L, Dan HC, Sun M, Liu Q, Sun XM, Feldman RI et al (2004) Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt. Cancer Res 64:4394–4399PubMedCrossRef Yang L, Dan HC, Sun M, Liu Q, Sun XM, Feldman RI et al (2004) Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt. Cancer Res 64:4394–4399PubMedCrossRef
19.
Zurück zum Zitat Sun M, Wang G, Paciga JE, Feldman RI, Yuan ZQ, Ma XL et al (2001) AKT1/PKBalpha kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells. Am J Pathol 159:431–437PubMedCrossRef Sun M, Wang G, Paciga JE, Feldman RI, Yuan ZQ, Ma XL et al (2001) AKT1/PKBalpha kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells. Am J Pathol 159:431–437PubMedCrossRef
20.
Zurück zum Zitat Segrelles C, Ruiz S, Perez P, Murga C, Santos M, Budunova IV et al (2002) Functional roles of Akt signaling in mouse skin tumorigenesis. Oncogene 21:53–64PubMedCrossRef Segrelles C, Ruiz S, Perez P, Murga C, Santos M, Budunova IV et al (2002) Functional roles of Akt signaling in mouse skin tumorigenesis. Oncogene 21:53–64PubMedCrossRef
21.
Zurück zum Zitat Affara NI, Schanbacher BL, Mihm MJ, Cook AC, Pei P, Mallery SR et al (2004) Activated Akt-1 in specific cell populations during multi-stage skin carcinogenesis. Anticancer Res 24:2773–2782PubMed Affara NI, Schanbacher BL, Mihm MJ, Cook AC, Pei P, Mallery SR et al (2004) Activated Akt-1 in specific cell populations during multi-stage skin carcinogenesis. Anticancer Res 24:2773–2782PubMed
22.
Zurück zum Zitat Malik SN, Brattain M, Ghosh PM, Troyer DA, Prihoda T, Bedolla R et al (2002) Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer. Clin Cancer Res 8:1168–1171PubMed Malik SN, Brattain M, Ghosh PM, Troyer DA, Prihoda T, Bedolla R et al (2002) Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer. Clin Cancer Res 8:1168–1171PubMed
23.
Zurück zum Zitat Kreisberg JI, Malik SN, Prihoda TJ, Bedolla RG, Troyer DA, Kreisberg S et al (2004) Phosphorylation of Akt (Ser473) is an excellent predictor of poor clinical outcome in prostate cancer. Cancer Res 64:5232–5236PubMedCrossRef Kreisberg JI, Malik SN, Prihoda TJ, Bedolla RG, Troyer DA, Kreisberg S et al (2004) Phosphorylation of Akt (Ser473) is an excellent predictor of poor clinical outcome in prostate cancer. Cancer Res 64:5232–5236PubMedCrossRef
24.
Zurück zum Zitat Antonyak MA, Kenyon LC, Godwin AK, James DC, Emlet DR, Okamoto I et al (2002) Elevated JNK activation contributes to the pathogenesis of human brain tumors. Oncogene 21:5038–5046PubMedCrossRef Antonyak MA, Kenyon LC, Godwin AK, James DC, Emlet DR, Okamoto I et al (2002) Elevated JNK activation contributes to the pathogenesis of human brain tumors. Oncogene 21:5038–5046PubMedCrossRef
25.
Zurück zum Zitat Engelberg D (2004) Stress-activated protein kinases - tumor suppressors or tumor initiators? Semin Cancer Biol 14:271–282PubMedCrossRef Engelberg D (2004) Stress-activated protein kinases - tumor suppressors or tumor initiators? Semin Cancer Biol 14:271–282PubMedCrossRef
26.
Zurück zum Zitat Khatlani TS, Wislez M, Sun M, Srinivas H, Iwanaga K, Ma L et al (2007) c-Jun N-terminal kinase is activated in non-small-cell lung cancer and promotes neoplastic transformation in human bronchial epithelial cells. Oncogene 26:2658–2666PubMedCrossRef Khatlani TS, Wislez M, Sun M, Srinivas H, Iwanaga K, Ma L et al (2007) c-Jun N-terminal kinase is activated in non-small-cell lung cancer and promotes neoplastic transformation in human bronchial epithelial cells. Oncogene 26:2658–2666PubMedCrossRef
27.
Zurück zum Zitat Cutler HG, Crumley F, Cox R (1980) Chaetoglobosin K: a new plant growth inhibitor and toxin from Diplodia macrospora. J Agric Food Chem 28:139–142PubMedCrossRef Cutler HG, Crumley F, Cox R (1980) Chaetoglobosin K: a new plant growth inhibitor and toxin from Diplodia macrospora. J Agric Food Chem 28:139–142PubMedCrossRef
28.
Zurück zum Zitat Tikoo A, Cutler H, Lo SH, Chen LB, Maruta H (1999) Treatment of Ras-induced cancers by the F-actin cappers Tensin and Chaetoglobosin K, in combination with the Caspase-1 inhibitor N1445. Cancer J Sci Am 5:293–300PubMed Tikoo A, Cutler H, Lo SH, Chen LB, Maruta H (1999) Treatment of Ras-induced cancers by the F-actin cappers Tensin and Chaetoglobosin K, in combination with the Caspase-1 inhibitor N1445. Cancer J Sci Am 5:293–300PubMed
29.
Zurück zum Zitat Matesic DF, Villio KN, Folse SL, Garcia EL, Cutler SJ, Cutler HG (2006) Inhibition of cytokinesis and Akt phosphorylation by chaetoglobosin K in ras-transformed epithelial cells. Cancer Chemother Pharmocol 57:741–754CrossRef Matesic DF, Villio KN, Folse SL, Garcia EL, Cutler SJ, Cutler HG (2006) Inhibition of cytokinesis and Akt phosphorylation by chaetoglobosin K in ras-transformed epithelial cells. Cancer Chemother Pharmocol 57:741–754CrossRef
30.
Zurück zum Zitat Matesic DF, Blommel ML, Sunman JA, Cutler SJ, Cutler HG (2001) Prevention of organochlorine-induced inhibition of gap junctional communication by chaetoglobosin K in astrocytes. Cell Biol Toxicol 17:395–408PubMedCrossRef Matesic DF, Blommel ML, Sunman JA, Cutler SJ, Cutler HG (2001) Prevention of organochlorine-induced inhibition of gap junctional communication by chaetoglobosin K in astrocytes. Cell Biol Toxicol 17:395–408PubMedCrossRef
31.
Zurück zum Zitat Sidorova TS, Matesic DF (2008) Protective effect of the natural product, Chaetoglobosin K, on lindane- and dieldrin-induced changes in astroglia: identification of activated signaling pathways. Pharm Res 25:1297–1308PubMedCrossRef Sidorova TS, Matesic DF (2008) Protective effect of the natural product, Chaetoglobosin K, on lindane- and dieldrin-induced changes in astroglia: identification of activated signaling pathways. Pharm Res 25:1297–1308PubMedCrossRef
32.
Zurück zum Zitat Engelman JA, Chen L, Tan X, Crosby K, Guimaraes AR, Upadhyay R et al (2008) Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 14:1351–1356PubMedCrossRef Engelman JA, Chen L, Tan X, Crosby K, Guimaraes AR, Upadhyay R et al (2008) Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 14:1351–1356PubMedCrossRef
33.
Zurück zum Zitat Sarbassov DD, Guertin DA, Ali SM, Sabatini DM (2005) Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307:1098–1101PubMedCrossRef Sarbassov DD, Guertin DA, Ali SM, Sabatini DM (2005) Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307:1098–1101PubMedCrossRef
34.
Zurück zum Zitat Kwon T, Kwon DY, Chun J, Kim JH, Kang SS (2000) Akt protein kinase inhibits Rac1-GTP binding through phosphorylation at serine 71 of Rac1. J Biol Chem 275:423–428PubMedCrossRef Kwon T, Kwon DY, Chun J, Kim JH, Kang SS (2000) Akt protein kinase inhibits Rac1-GTP binding through phosphorylation at serine 71 of Rac1. J Biol Chem 275:423–428PubMedCrossRef
35.
Zurück zum Zitat Murga C, Zohar M, Teramoto H, Gutkind JS (2002) Rac1 and RhoG promote cell survival by the activation of PI3K and Akt, independently of their ability to stimulate JNK and NF-kappaB. Oncogene 21:207–216PubMedCrossRef Murga C, Zohar M, Teramoto H, Gutkind JS (2002) Rac1 and RhoG promote cell survival by the activation of PI3K and Akt, independently of their ability to stimulate JNK and NF-kappaB. Oncogene 21:207–216PubMedCrossRef
36.
Zurück zum Zitat Zhang QG, Wang XT, Han D, Yin XH, Zhang GY, Xu TL (2006) Akt inhibits MLK3/JNK3 signaling by inactivating Rac1: a protective mechanism against ischemic brain injury. J Neurochem 98:1886–1898PubMedCrossRef Zhang QG, Wang XT, Han D, Yin XH, Zhang GY, Xu TL (2006) Akt inhibits MLK3/JNK3 signaling by inactivating Rac1: a protective mechanism against ischemic brain injury. J Neurochem 98:1886–1898PubMedCrossRef
37.
Zurück zum Zitat Logan MR, Mandato CA (2006) Regulation of the actin cytoskeleton by PIP2 in cytokinesis. Biol Cell 98:377–388PubMedCrossRef Logan MR, Mandato CA (2006) Regulation of the actin cytoskeleton by PIP2 in cytokinesis. Biol Cell 98:377–388PubMedCrossRef
38.
Zurück zum Zitat Canman JC, Lewellyn L, Laband K, Smerdon SJ, Desai A, Bowerman B, Oegema K (2008) Inhibition of Rac by the GAP activity of centralspindlin is essential for cytokinesis. Science 322:1543–1546PubMedCrossRef Canman JC, Lewellyn L, Laband K, Smerdon SJ, Desai A, Bowerman B, Oegema K (2008) Inhibition of Rac by the GAP activity of centralspindlin is essential for cytokinesis. Science 322:1543–1546PubMedCrossRef
39.
Zurück zum Zitat Lim CP, Cao X (1999) Serine phosphorylation and negative regulation of Stat3 by JNK. J Biol Chem 274:31055–31061PubMedCrossRef Lim CP, Cao X (1999) Serine phosphorylation and negative regulation of Stat3 by JNK. J Biol Chem 274:31055–31061PubMedCrossRef
40.
Zurück zum Zitat Rawlings JS, Rosler KM, Harrison DA (2004) The JAK/STAT signaling pathway. J Cell Sci 117:1281–1283PubMedCrossRef Rawlings JS, Rosler KM, Harrison DA (2004) The JAK/STAT signaling pathway. J Cell Sci 117:1281–1283PubMedCrossRef
41.
Zurück zum Zitat Wong MK, Lo AI, Lam B, Lam WK, Ip MS, Ho JC (2010) Erlotinib as salvage treatment after failure to first-line gefitinib in non-small cell lung cancer. Cancer Chemother Pharmacol 65:1023–1028PubMedCrossRef Wong MK, Lo AI, Lam B, Lam WK, Ip MS, Ho JC (2010) Erlotinib as salvage treatment after failure to first-line gefitinib in non-small cell lung cancer. Cancer Chemother Pharmacol 65:1023–1028PubMedCrossRef
Metadaten
Titel
Dual modulation of JNK and Akt signaling pathways by chaetoglobosin K in human lung carcinoma and ras-transformed epithelial cells
verfasst von
Amna Ali
Tatyana S. Sidorova
Diane F. Matesic
Publikationsdatum
01.06.2013
Verlag
Springer US
Erschienen in
Investigational New Drugs / Ausgabe 3/2013
Print ISSN: 0167-6997
Elektronische ISSN: 1573-0646
DOI
https://doi.org/10.1007/s10637-012-9883-x

Weitere Artikel der Ausgabe 3/2013

Investigational New Drugs 3/2013 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.